28
views
views
The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.
Indian biotech firm Panacea Biotec Ltd said on Wednesday it would partner with US-based Refana Inc to make a potential vaccine for Covid-19.
The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.
Panacea's shares jumped 20 per cent in morning trading on India's National Stock Exchange after the news.
Comments
0 comment